FDA approved Imfinzi with gemcitabine and cisplatin for muscle-invasive bladder cancer, based on NIAGARA trial results showing improved survival outcomes. The regimen integrates immunotherapy in pre- ...

Bavencio improved survival in patients with bladder cancer, irrespective of diabetes status, according to an analysis of the JAVELIN Bladder 100 trial. Previous data showed that in the phase 3 JAVELIN ...

Johnson & Johnson's confidence in its bladder cancer therapy TAR-200 – dented by a negative phase 3 readout last year – seems to be justified. New data from the SunRISe-1 study of TAR-200 in ...

Cystectomy often treats bladder cancer. But bladder removal surgery can help other bladder problems, too. After cystectomy, your urine may need a new route to exit your body (urinary diversion).

Results from the Phase IIb SunRISe-1 study demonstrated a one-year duration of response with the TAR-200 intravesical gemcitabine-releasing system in patients with Bacillus ...

high-risk non-muscle invasive bladder cancer "Patients with bladder cancer need more effective treatment options that are both tolerable and easily incorporated into everyday practice, especially ...

Oral presentation provides update from QUILT-3.032 on durable complete responses to ANKTIVA ® plus BCG in BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ (NMIBC CIS ...

A new comparative study has thrown light on the capabilities and shortcomings of large language models (LLMs) in delivering critical cancer-related health information to the public. Published in the ...

It is estimated that this year alone, some 81,000 cases of bladder cancer will be diagnosed just in the United States. The most common type of bladder cancer, urothelial carcinoma, develops in the ...

Patients with tumors in the trigone and urethra were more likely to experience recurrence and cancer-specific death after radical cystectomy than patients with tumor only in the bladder walls.

3 "Patients with bladder cancer need more effective treatment options that are both tolerable and easily incorporated into everyday practice, especially for those with HR-NMIBC, a highly recurrent ...

TAR-200 is a groundbreaking therapy for early-stage bladder cancer, designed to deliver a sustained local release of medication directly into the bladder—right where it is needed," said Biljana ...